Metropolitan Life Insurance Company (MetLife)’s Syndax Pharmaceuticals SNDX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,150	Closed	-$98.8K	–	1810
2024 Q1	$98.8K	Buy	4,150 +343	+9%	+$7.65K	﹤0.01%	1056
2023 Q4	$82.3K	Hold	3,807	–	–	﹤0.01%	1189
2023 Q3	$55.3K	Buy	3,807 +205	+6%	+$3.88K	﹤0.01%	1349
2023 Q2	$75.4K	Buy	3,602 +348	+11%	+$7.25K	﹤0.01%	1179
2023 Q1	$68.7K	Sell	3,254 -37	-1%	-$920	﹤0.01%	1204
2022 Q4	$83.8K	Buy	3,291 +210	+7%	+$4.9K	﹤0.01%	1156
2022 Q3	$74K	Hold	3,081	–	–	﹤0.01%	1200
2022 Q2	$59.3K	Hold	3,081	–	–	﹤0.01%	1391
2022 Q1	$53.5K	Sell	3,081 -9,976	-76%	-$168K	﹤0.01%	1556
2021 Q4	$286K	Hold	13,057	–	–	﹤0.01%	1768
2021 Q3	$250K	Hold	13,057	–	–	﹤0.01%	1910
2021 Q2	$224K	Buy	13,057 +5,127	+65%	+$93.9K	﹤0.01%	2060
2021 Q1	$177K	Hold	7,930	–	–	﹤0.01%	2101
2020 Q4	$176K	Hold	7,930	–	–	﹤0.01%	2015
2020 Q3	$117K	Hold	7,930	–	–	﹤0.01%	2129
2020 Q2	$118K	Hold	7,930	–	–	﹤0.01%	2152
2020 Q1	$87K	Buy	+7,930	New	+$74.4K	﹤0.01%	2115

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s SNDX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Syndax Pharmaceuticals (SNDX) in Q2 2024, closing a stake of 4,150 shares — an estimated $98.8K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in SNDX in Q1 2020 and held it in 17 quarters. The position peaked at $286K in Q4 2021. 196 funds tracked by Wall St. Rank hold SNDX as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Syndax Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 4,150 Syndax Pharmaceuticals shares in Q2 2024, an estimated $98.8K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Syndax Pharmaceuticals in Q1 2020 and held it in 17 quarters.
Metropolitan Life Insurance Company (MetLife)'s Syndax Pharmaceuticals position peaked at $286K in Q4 2021.
196 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.